A Phase 3 interventional study of Secukinumab and Placebo in Non-radiographic Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 139 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 13 in phase 3, and was the 9th registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
CARE ARTHRITIS LTD. · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 555 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 200 across the 31 interventional studies, 50 across the 3 observational. Of the 21 that completed or were terminated, 17 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 8 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07836374University of MichiganRENEW Intervention for Axial Spondyloarthritis | 2027-03 |
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT07642622University of WashingtonPhysical Activity Through Health Technology in Axial Spondyloarthritis | 2027-04 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208
Patients were randomized to one of three treatment groups (1:1:1) in the core phase:
All patients received secukinumab 150 mg as open-label treatment from Week 52 up to Week 100, unless they had discontinued study treatment.
At Week 104, all patients who finished the core phase according to the protocol were asked to continue in an optional, exploratory extension phase. Patients who achieved ASAS20 response at Week 104 (Core Phase Responders) were randomized to the following treatment groups (blinded) in the extension phase:
Core Phase Non-Responders (not achieving ASAS20 at Week 104) were escalated to secukinumab 300 mg in an open-label manner.
Starting from Week 156 onward, a patient could switch to secukinumab 300 mg open-label based on the clinical judgment of disease activity by the investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase
Drug: Secukinumab
Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase
Drug: Secukinumab
Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase
Drug: Placebo
Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase
Drug: Secukinumab · Drug: Placebo
Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase
Drug: Secukinumab
Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase
Drug: Secukinumab
Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
Also known as: AIN457
Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Also known as: AIN457
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
Time frame: Week 16
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
Time frame: Week 52
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
Time frame: Week 16 and week 52
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity.
Time frame: Week 16
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity.
Time frame: Week 16
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. A higher score on the VAS signifies higher severity.
Time frame: Week 16
Change in Bath Ankylosing Spondylitis Functional Index (BASFI)
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those subjects with AS. The ten questions were chosen with a major input from subjects with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects' ability to cope with everyday life. A 100 mm visual analog scale (VAS) is used to answer the questions. The mean of the ten questions gives the BASFI score - a value between 0 and 10. (0 being no problem and 10 being the worst problem, captured as a continuous visual analog scale (VAS)). A higher score on the VAS signifies higher severity.
Time frame: Baseline and Week 16
The Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS. The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline. A higher score on the VAS signifies higher severity.
Time frame: Week 16 and 52
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated assessment tool using 1 through 10 scales (1 indicating "no problem" and 10 indicating " worst problem"), to characterize six clinical domains (fatigue, spinal pain, joint pain/selling, localized tenderness, morning stiffness duration, morning stiffness severity) pertaining to five major symptoms of Ankylosing Spondylitis (AS). The computed final BASDAI score is a value between 0 and 10 with a higher score indicating worse disease. A higher score on the VAS signifies higher severity.
Time frame: Baseline and Week 16
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16
The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete.
Time frame: Baseline and Week 16
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52
The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete. Summary statistics are presented for participants (n) without intercurrent events.
Time frame: Baseline and Week 52
The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease
Ankylosing Spondylitis Disease Activity Score (ASDAS) - C-reactive protein (CRP) inactive disease criteria are defined as a value below 1.3. Higher score indicates worse symptoms. The formula is: ASDAS-CRP = 0.121 x total back pain + 0.110 x patient global + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(hsCRP +1)
Time frame: Week 52
Change in High Sensitivity C-reactive Protein
High sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study.
Time frame: Baseline and Week 16
Change in Short Form-36 Physical Component Summary (SF-36 PCS)
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 16
Change in Sacroiliac Joint Edema - Week 16
Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.
Time frame: Baseline and Week 16
Change in Sacroiliac Joint Edema - Week 52
Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.
Time frame: Baseline and Week 52
A total of 1583 patients were screened for this study, of which 555 patients (35.1%) were randomized. Overall, 1028 patients (64.9%) discontinued prior to screening phase completion, most due to screen failure (1000 patients, 63.2%).
| Milestone | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | AIN457 150 mg Extension Phase | AIN457 300 mg Extension Phase | AIN457 300 mg Open Label Extension Phase |
|---|---|---|---|---|---|---|
| Started | 185 | 184 | 186 | 0 | 0 | 0 |
| Completed | 175 | 177 | 175 | 0 | 0 | 0 |
| Not completed | 10 | 7 | 11 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 4 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 5 | 0 | 0 | 0 |
| Milestone | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | AIN457 150 mg Extension Phase | AIN457 300 mg Extension Phase | AIN457 300 mg Open Label Extension Phase |
|---|---|---|---|---|---|---|
| Started | 185 | 184 | 186 | 0 | 0 | 0 |
| Completed | 156 | 165 | 160 | 0 | 0 | 0 |
| Not completed | 29 | 19 | 26 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 5 | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 10 | 7 | 11 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 3 | 9 | 0 | 0 | 0 |
| Milestone | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | AIN457 150 mg Extension Phase | AIN457 300 mg Extension Phase | AIN457 300 mg Open Label Extension Phase |
|---|---|---|---|---|---|---|
| Started | 185 | 184 | 186 | 0 | 0 | 0 |
| Completed | 146 | 143 | 149 | 0 | 0 | 0 |
| Not completed | 39 | 41 | 37 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 10 | 16 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 13 | 12 | 11 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 11 | 5 | 0 | 0 | 0 |
| Withdrew: Pt completed wk 52. withdrawal by subject at wk 52. | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | AIN457 150 mg Extension Phase | AIN457 300 mg Extension Phase | AIN457 300 mg Open Label Extension Phase |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 147 | 147 | 78 |
| Completed | 0 | 0 | 0 | 137 | 132 | 72 |
| Not completed | 0 | 0 | 0 | 10 | 15 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 | 8 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Non-compliance with study treatment | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 4 | 1 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16 | 68 | 70 | 50 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52 | 58 | 66 | 34 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| week 16 | 74 | 75 | 52 |
| week 52 | 62 | 70 | 36 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response | 105 | 107 | 85 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response | 74 | 66 | 44 |
Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR) | 40 | 39 | 13 |
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those subjects with AS. The ten questions were chosen with a major input from subjects with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects' ability to cope with everyday life. A 100 mm visual analog scale (VAS) is used to answer the questions. The mean of the ten questions gives the BASFI score - a value between 0 and 10. (0 being no problem and 10 being the worst problem, captured as a continuous visual analog scale (VAS)). A higher score on the VAS signifies higher severity.
| Index | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Bath Ankylosing Spondylitis Functional Index (BASFI) | -1.75 ± 0.202 | -1.64 ± 0.204 | -1.01 ± 0.206 |
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS. The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline. A higher score on the VAS signifies higher severity.
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| week 16 | 69 | 69 | 39 |
| week 52 | 57 | 65 | 37 |
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated assessment tool using 1 through 10 scales (1 indicating "no problem" and 10 indicating " worst problem"), to characterize six clinical domains (fatigue, spinal pain, joint pain/selling, localized tenderness, morning stiffness duration, morning stiffness severity) pertaining to five major symptoms of Ankylosing Spondylitis (AS). The computed final BASDAI score is a value between 0 and 10 with a higher score indicating worse disease. A higher score on the VAS signifies higher severity.
| scores on a scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -2.35 ± 0.201 | -2.43 ± 0.203 | -1.46 ± 0.205 |
The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete.
| Scores on a scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16 | -3.45 ± 0.408 | -3.62 ± 0.414 | -1.84 ± 0.421 |
The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete. Summary statistics are presented for participants (n) without intercurrent events.
| Scores on a scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52 | -7.1 ± 4.77 | -7.6 ± 5.38 | -6.4 ± 4.64 |
Ankylosing Spondylitis Disease Activity Score (ASDAS) - C-reactive protein (CRP) inactive disease criteria are defined as a value below 1.3. Higher score indicates worse symptoms. The formula is: ASDAS-CRP = 0.121 x total back pain + 0.110 x patient global + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(hsCRP +1)
| Participants | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease | 29 | 44 | 19 |
High sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study.
| ratio | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in High Sensitivity C-reactive Protein | 0.64 ± 1.078 | 0.64 ± 1.079 | 0.91 ± 1.080 |
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
| Scores on a Scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Short Form-36 Physical Component Summary (SF-36 PCS) | 5.71 ± 0.683 | 5.57 ± 0.694 | 2.93 ± 0.705 |
Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.
| Scores on a Scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Sacroiliac Joint Edema - Week 16 | -1.68 ± 0.24 | -1.03 ± 0.18 | -0.39 ± 0.15 |
Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.
| Scores on a scale | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase |
|---|---|---|---|
| Change in Sacroiliac Joint Edema - Week 52 | -2.9 ± 4.54 | -1.9 ± 3.40 | -0.1 ± 1.97 |
Collected over Adverse events are reported from first dose of study treatment until end of study treatment plus 12 wks post-treatment, up to a maximum timeframe of 1520 days (approx. 4.2 years). Safety results summarize long term data for all patients for the entire period of their study participation, which, for the majority of pts, combines the core phase and the extension phase (not all pts participated in the extension). The table is presented by dose group, AIN457 150 mg and AIN457 300 mg and placebo.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any AIN457 150 mg, in Core Phase and Extension Phase | 0/543 (0%) | 48/543 (8.8%) | 320/543 (58.9%) |
| Any AIN457 300 mg in Extension Phase | 0/254 (0%) | 11/254 (4.3%) | 74/254 (29.1%) |
| Any AIN457, In Core Phase and Extension Phase | 0/543 (0%) | 58/543 (10.7%) | 335/543 (61.7%) |
| Placebo, Core Phase | 0/186 (0%) | 8/186 (4.3%) | 67/186 (36%) |
| Event | Any AIN457 150 mg, in Core Phase and Extension Phase | Any AIN457 300 mg in Extension Phase | Any AIN457, In Core Phase and Extension Phase | Placebo, Core Phase |
|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 2/543 | 1/254 | 3/543 | 0/186 |
| TonsillitisInfections and infestations | 3/543 | 0/254 | 3/543 | 0/186 |
| ArthritisMusculoskeletal and connective tissue disorders | 3/543 | 0/254 | 3/543 | 0/186 |
| Acute coronary syndromeCardiac disorders | 0/543 | 0/254 | 0/543 | 1/186 |
| Myocardial infarctionCardiac disorders | 0/543 | 0/254 | 0/543 | 1/186 |
| PyrexiaGeneral disorders | 0/543 | 0/254 | 0/543 | 1/186 |
| Viral tracheitisInfections and infestations | 0/543 | 0/254 | 0/543 | 1/186 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/543 | 0/254 | 0/543 | 1/186 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/543 | 0/254 | 0/543 | 1/186 |
| Back painMusculoskeletal and connective tissue disorders | 1/543 | 0/254 | 1/543 | 1/186 |
| Event | Any AIN457 150 mg, in Core Phase and Extension Phase | Any AIN457 300 mg in Extension Phase | Any AIN457, In Core Phase and Extension Phase | Placebo, Core Phase |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 137/543 | 33/254 | 146/543 | 32/186 |
| Upper respiratory tract infectionInfections and infestations | 65/543 | 16/254 | 77/543 | 13/186 |
| HeadacheNervous system disorders | 61/543 | 7/254 | 65/543 | 9/186 |
| DiarrhoeaGastrointestinal disorders | 55/543 | 6/254 | 61/543 | 10/186 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 43/543 | 6/254 | 48/543 | 9/186 |
| Urinary tract infectionInfections and infestations | 38/543 | 9/254 | 42/543 | 4/186 |
| Back painMusculoskeletal and connective tissue disorders | 36/543 | 3/254 | 38/543 | 3/186 |
| SinusitisInfections and infestations | 30/543 | 5/254 | 34/543 | 3/186 |
| HypertensionVascular disorders | 29/543 | 5/254 | 34/543 | 3/186 |
| PharyngitisInfections and infestations | 27/543 | 5/254 | 31/543 | 1/186 |
| Age, Categorical(Participants) | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 183 | 180 | 183 | 546 |
| >=65 years | 2 | 4 | 3 | 9 |
| Age, Continuous(Years) | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | Total |
|---|---|---|---|---|
| Mean | 39.1 ± 11.45 | 39.8 ± 11.68 | 39.3 ± 11.47 | 39.4 ± 11.52 |
| Sex: Female, Male(Participants) | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | Total |
|---|---|---|---|---|
| Female | 105 | 100 | 95 | 300 |
| Male | 80 | 84 | 91 | 255 |
| Ethnicity (NIH/OMB)(Participants) | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 7 | 24 |
| Not Hispanic or Latino | 165 | 162 | 161 | 488 |
| Unknown or Not Reported | 11 | 14 | 18 | 43 |
| Race/Ethnicity, Customized(Participants) | Secukinumab, Load, Core Phase | Secukinumab, No Load, Core Phase | Placebo, Core Phase | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 4 | 8 | 11 | 23 |
| Black or African American | 0 | 2 | 1 | 3 |
| White | 176 | 165 | 167 | 508 |
| Other | 5 | 7 | 7 | 19 |
Showing the first 100 of 139 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2016 to primary completion in Jul 2019, 38 months.
Results were first posted in Aug 2020, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab